Professional Documents
Culture Documents
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
1. Primera generacin
2. Segunda generacin
3. Tercera generacin
4. Cuarta generacin
5. Quinta generacin
______________________________
______________________________
______________________________
______________________________
A) (A,1)(B,2)(C,3)(D,4)(E,5)
B) (A,3)(B,1)(C,5)(D,2)(E,4)
C) (A,5)(B,1)(C,3)(D,2)(E,4)
D) (A,2)(B,4)(C,5)(D,3)(E,1)
E) (A,5)(B,4)(C,3)(D,2)(E,1)
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
17. En una paciente de 60 aos con ITU por E. coli resistente a cefalosporinas de 3ra
generacin. Cul de los siguientes carbapenems usara de preferencia?
A) Imipenem
B) Ertapenem
C) Meropenem
D) Doripenem
E) Ninguno
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
21. El Sindrome del hombre rojo, puede verse durante la administracin de:
A) Oxacilina
B) Ceftobiprole
C) Vancomicina
D) Teicoplamina
E) Daptomicina
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
27. El aminoglucsido, frente al cual las bacterias desarrollan resistencia con mayor
dificultad respecto a las dems, es:
A) Gentamicina
B) Streptomicina
C) Amikacina
D) Neomicina
E) Paromomicina
28. Los aminoglucsidos, luego de la administracin EV, logran alcanzar
concentraciones muy bajas a nivel de todo lo siguiente, excepto:
A) Piel y tejidos blandos
B) Pulmones
C) Prstata
D) Vas urinarias
E) Sistema Nervioso Central
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
__________________